CovidFranceV1, Main, Exploration, bibRecord, 000082

[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].

Identifieur interne : 000082 ( Main/Exploration ); précédent : 000081; suivant : 000083

[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].

Auteurs : N. Bouaziz [France] ; H. Ben Rejeb [France] ; S. Ateb [France] ; T. Fourati [France] ; F. Chammas [France] ; D. Baha [France] ; R. Rosetti [France] ; K. Kalalou [France] ; G. Saba [France] ; R. Benadhira [France] ; D. Januel [France]

Source :

L'Encephale [ 0013-7006 ] ; 2020.

RBID : pubmed:32475694

Descripteurs français

English descriptors

KwdEn :
- Anticonvulsants (administration & dosage), Anticonvulsants (therapeutic use), Antipsychotic Agents (administration & dosage), Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Betacoronavirus (MeSH), Clozapine (administration & dosage), Clozapine (adverse effects), Clozapine (therapeutic use), Coronavirus Infections (complications), Delayed-Action Preparations (MeSH), Drug Resistance (MeSH), Drug Therapy, Combination (MeSH), Humans (MeSH), Immunologic Factors (administration & dosage), Immunologic Factors (adverse effects), Immunologic Factors (therapeutic use), Lithium Carbonate (administration & dosage), Lithium Carbonate (therapeutic use), Male (MeSH), Middle Aged (MeSH), Paliperidone Palmitate (administration & dosage), Paliperidone Palmitate (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (complications), Psychotic Disorders (drug therapy), Sialorrhea (chemically induced), Treatment Outcome (MeSH), Valproic Acid (administration & dosage), Valproic Acid (therapeutic use).
MESH :
- chemical , administration & dosage : Anticonvulsants, Antipsychotic Agents, Clozapine, Immunologic Factors, Lithium Carbonate, Paliperidone Palmitate, Valproic Acid.
- chemical , adverse effects : Antipsychotic Agents, Clozapine, Immunologic Factors.
- chemical , therapeutic use : Anticonvulsants, Antipsychotic Agents, Clozapine, Immunologic Factors, Lithium Carbonate, Paliperidone Palmitate, Valproic Acid.
- chemically induced : Sialorrhea.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Psychotic Disorders.
- Betacoronavirus, Delayed-Action Preparations, Drug Resistance, Drug Therapy, Combination, Humans, Male, Middle Aged, Pandemics, Treatment Outcome.

DOI: 10.1016/j.encep.2020.05.009
PubMed: 32475694
PubMed Central: PMC7241412

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001019
to stream Main, to step Curation: 001019

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].</title>
<author><name sortKey="Bouaziz, N" sort="Bouaziz, N" uniqKey="Bouaziz N" first="N" last="Bouaziz">N. Bouaziz</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France. Electronic address: bouaziznoomane@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ben Rejeb, H" sort="Ben Rejeb, H" uniqKey="Ben Rejeb H" first="H" last="Ben Rejeb">H. Ben Rejeb</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ateb, S" sort="Ateb, S" uniqKey="Ateb S" first="S" last="Ateb">S. Ateb</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fourati, T" sort="Fourati, T" uniqKey="Fourati T" first="T" last="Fourati">T. Fourati</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chammas, F" sort="Chammas, F" uniqKey="Chammas F" first="F" last="Chammas">F. Chammas</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baha, D" sort="Baha, D" uniqKey="Baha D" first="D" last="Baha">D. Baha</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rosetti, R" sort="Rosetti, R" uniqKey="Rosetti R" first="R" last="Rosetti">R. Rosetti</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kalalou, K" sort="Kalalou, K" uniqKey="Kalalou K" first="K" last="Kalalou">K. Kalalou</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Saba, G" sort="Saba, G" uniqKey="Saba G" first="G" last="Saba">G. Saba</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benadhira, R" sort="Benadhira, R" uniqKey="Benadhira R" first="R" last="Benadhira">R. Benadhira</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Januel, D" sort="Januel, D" uniqKey="Januel D" first="D" last="Januel">D. Januel</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32475694</idno>
<idno type="pmid">32475694</idno>
<idno type="doi">10.1016/j.encep.2020.05.009</idno>
<idno type="pmc">PMC7241412</idno>
<idno type="wicri:Area/Main/Corpus">001019</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001019</idno>
<idno type="wicri:Area/Main/Curation">001019</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001019</idno>
<idno type="wicri:Area/Main/Exploration">001019</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].</title>
<author><name sortKey="Bouaziz, N" sort="Bouaziz, N" uniqKey="Bouaziz N" first="N" last="Bouaziz">N. Bouaziz</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France. Electronic address: bouaziznoomane@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ben Rejeb, H" sort="Ben Rejeb, H" uniqKey="Ben Rejeb H" first="H" last="Ben Rejeb">H. Ben Rejeb</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ateb, S" sort="Ateb, S" uniqKey="Ateb S" first="S" last="Ateb">S. Ateb</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fourati, T" sort="Fourati, T" uniqKey="Fourati T" first="T" last="Fourati">T. Fourati</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chammas, F" sort="Chammas, F" uniqKey="Chammas F" first="F" last="Chammas">F. Chammas</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baha, D" sort="Baha, D" uniqKey="Baha D" first="D" last="Baha">D. Baha</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rosetti, R" sort="Rosetti, R" uniqKey="Rosetti R" first="R" last="Rosetti">R. Rosetti</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kalalou, K" sort="Kalalou, K" uniqKey="Kalalou K" first="K" last="Kalalou">K. Kalalou</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Saba, G" sort="Saba, G" uniqKey="Saba G" first="G" last="Saba">G. Saba</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benadhira, R" sort="Benadhira, R" uniqKey="Benadhira R" first="R" last="Benadhira">R. Benadhira</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Januel, D" sort="Januel, D" uniqKey="Januel D" first="D" last="Januel">D. Januel</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Neuilly-sur-Marne</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">L'Encephale</title>
<idno type="ISSN">0013-7006</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticonvulsants (administration & dosage)</term>
<term>Anticonvulsants (therapeutic use)</term>
<term>Antipsychotic Agents (administration & dosage)</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Clozapine (administration & dosage)</term>
<term>Clozapine (adverse effects)</term>
<term>Clozapine (therapeutic use)</term>
<term>Coronavirus Infections (complications)</term>
<term>Delayed-Action Preparations (MeSH)</term>
<term>Drug Resistance (MeSH)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunologic Factors (administration & dosage)</term>
<term>Immunologic Factors (adverse effects)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Lithium Carbonate (administration & dosage)</term>
<term>Lithium Carbonate (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Paliperidone Palmitate (administration & dosage)</term>
<term>Paliperidone Palmitate (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Sialorrhea (chemically induced)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Valproic Acid (administration & dosage)</term>
<term>Valproic Acid (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide valproïque (administration et posologie)</term>
<term>Acide valproïque (usage thérapeutique)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Anticonvulsivants (administration et posologie)</term>
<term>Anticonvulsivants (usage thérapeutique)</term>
<term>Association de médicaments (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Carbonate de lithium (administration et posologie)</term>
<term>Carbonate de lithium (usage thérapeutique)</term>
<term>Clozapine (administration et posologie)</term>
<term>Clozapine (effets indésirables)</term>
<term>Clozapine (usage thérapeutique)</term>
<term>Facteurs immunologiques (administration et posologie)</term>
<term>Facteurs immunologiques (effets indésirables)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Mâle (MeSH)</term>
<term>Neuroleptiques (administration et posologie)</term>
<term>Neuroleptiques (effets indésirables)</term>
<term>Neuroleptiques (usage thérapeutique)</term>
<term>Palmitate de palipéridone (administration et posologie)</term>
<term>Palmitate de palipéridone (usage thérapeutique)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Préparations à action retardée (MeSH)</term>
<term>Ptyalisme (induit chimiquement)</term>
<term>Résistance aux substances (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Troubles psychotiques (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term>
<term>Antipsychotic Agents</term>
<term>Clozapine</term>
<term>Immunologic Factors</term>
<term>Lithium Carbonate</term>
<term>Paliperidone Palmitate</term>
<term>Valproic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Clozapine</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term>
<term>Antipsychotic Agents</term>
<term>Clozapine</term>
<term>Immunologic Factors</term>
<term>Lithium Carbonate</term>
<term>Paliperidone Palmitate</term>
<term>Valproic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acide valproïque</term>
<term>Anticonvulsivants</term>
<term>Carbonate de lithium</term>
<term>Clozapine</term>
<term>Facteurs immunologiques</term>
<term>Neuroleptiques</term>
<term>Palmitate de palipéridone</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Clozapine</term>
<term>Facteurs immunologiques</term>
<term>Infections à coronavirus</term>
<term>Neuroleptiques</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Ptyalisme</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Troubles psychotiques</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide valproïque</term>
<term>Anticonvulsivants</term>
<term>Carbonate de lithium</term>
<term>Clozapine</term>
<term>Facteurs immunologiques</term>
<term>Neuroleptiques</term>
<term>Palmitate de palipéridone</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>Delayed-Action Preparations</term>
<term>Drug Resistance</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Betacoronavirus</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pandémies</term>
<term>Préparations à action retardée</term>
<term>Résistance aux substances</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32475694</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>46</Volume>
<Issue>3S</Issue>
<PubDate><Year>2020</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>L'Encephale</Title>
<ISOAbbreviation>Encephale</ISOAbbreviation>
</Journal>
<ArticleTitle>[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].</ArticleTitle>
<Pagination><MedlinePgn>S126-S127</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0013-7006(20)30094-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2020.05.009</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bouaziz</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France. Electronic address: bouaziznoomane@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ben Rejeb</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ateb</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fourati</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chammas</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baha</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosetti</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kalalou</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Saba</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Benadhira</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Januel</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Réflexions autour d’une évolution favorable d’une COVID-19 chez un patient présentant une schizophrénie résistante et sous une association clozapine et palipéridone palmitate.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Encephale</MedlineTA>
<NlmUniqueID>7505643</NlmUniqueID>
<ISSNLinking>0013-7006</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber>
<NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber>
<NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber>
<NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>R8P8USM8FR</RegistryNumber>
<NameOfSubstance UI="D000068882">Paliperidone Palmitate</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068882" MajorTopicYN="N">Paliperidone Palmitate</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012798" MajorTopicYN="N">Sialorrhea</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32475694</ArticleId>
<ArticleId IdType="pii">S0013-7006(20)30094-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.encep.2020.05.009</ArticleId>
<ArticleId IdType="pmc">PMC7241412</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Neuilly-sur-Marne</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Bouaziz, N" sort="Bouaziz, N" uniqKey="Bouaziz N" first="N" last="Bouaziz">N. Bouaziz</name>
</region>
<name sortKey="Ateb, S" sort="Ateb, S" uniqKey="Ateb S" first="S" last="Ateb">S. Ateb</name>
<name sortKey="Baha, D" sort="Baha, D" uniqKey="Baha D" first="D" last="Baha">D. Baha</name>
<name sortKey="Ben Rejeb, H" sort="Ben Rejeb, H" uniqKey="Ben Rejeb H" first="H" last="Ben Rejeb">H. Ben Rejeb</name>
<name sortKey="Benadhira, R" sort="Benadhira, R" uniqKey="Benadhira R" first="R" last="Benadhira">R. Benadhira</name>
<name sortKey="Chammas, F" sort="Chammas, F" uniqKey="Chammas F" first="F" last="Chammas">F. Chammas</name>
<name sortKey="Fourati, T" sort="Fourati, T" uniqKey="Fourati T" first="T" last="Fourati">T. Fourati</name>
<name sortKey="Januel, D" sort="Januel, D" uniqKey="Januel D" first="D" last="Januel">D. Januel</name>
<name sortKey="Kalalou, K" sort="Kalalou, K" uniqKey="Kalalou K" first="K" last="Kalalou">K. Kalalou</name>
<name sortKey="Rosetti, R" sort="Rosetti, R" uniqKey="Rosetti R" first="R" last="Rosetti">R. Rosetti</name>
<name sortKey="Saba, G" sort="Saba, G" uniqKey="Saba G" first="G" last="Saba">G. Saba</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000082 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000082 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32475694
   |texte=   [Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32475694" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].

[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki